BlackRock, Inc. Acquires 6.9% Stake in Soleno Therapeutics Inc (SLNO)

On April 24, 2026, BlackRock, Inc. filed a Schedule 13G/A with the SEC, reporting a significant new ownership stake in Soleno Therapeutics Inc (SLNO). As of the event date on March 31, 2026, BlackRock beneficially owns 3,543,296 shares of common stock, representing 6.9% of the company. This filing marks an increase from a previous 0.0% position, indicating a substantial recent accumulation of shares. The filing specifies that BlackRock holds sole dispositive power over all 3,543,296 shares and sole voting power over 3,471,113 shares. The securities were acquired in the ordinary course of business, and the filing indicates that the acquisition was not intended to influence or change the control of the issuer. Various subsidiaries under the BlackRock parent company are involved in this holding, though no single individual's interest exceeds 5% of the total outstanding shares. This amendment (Amendment No. 1) confirms BlackRock's status as a major institutional investor in the biopharmaceutical company.